{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:35Z","timestamp":1790188295863,"version":"4.1.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11095-022-03302-1","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T18:18:00Z","timestamp":1654107480000},"page":"1233-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review"],"prefix":"10.1007","volume":"39","author":[{"given":"Manoj K.","family":"Mahapatra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthukumar","family":"Karuppasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswa M.","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"3302_CR1","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2337\/db16-1009","volume":"66","author":"FP Zummo","year":"2017","unstructured":"Zummo FP, Cullen KS, Honkanen-Scott M, Shaw JA, Lovat PE, Arden C. Glucagon-like peptide 1 protects pancreatic b-cells from death by increasing autophagic flux and restoring lysosomal function. Diabetes. 2017;66:1272\u201385. https:\/\/doi.org\/10.2337\/db16-1009.","journal-title":"Diabetes"},{"key":"3302_CR2","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/db09-0063","volume":"58","author":"M Cornu","year":"2009","unstructured":"Cornu M, Yang J-Y, Jaccard E, Poussin C, Widmann C, Thorens B. Glucagon like peptide-1 protects b-cells against apoptosis by increasing the activity of an IGF-2\/IGF-1 receptor autocrine loop. Diabetes. 2009;58:1816\u201325. https:\/\/doi.org\/10.2337\/db09-0063.","journal-title":"Diabetes"},{"issue":"12","key":"3302_CR3","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1161\/ATVBAHA.117.310251","volume":"37","author":"R Khound","year":"2017","unstructured":"Khound R, Taher J, Baker C, Adeli K, Su Q. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance. Arterioscler Thromb Vasc Biol. 2017;37(12):2252\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310251.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3302_CR4","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1152\/ajpendo.00069.2016","volume":"311","author":"T Jin","year":"2016","unstructured":"Jin T, Weng J. Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. Am J Physiol Endocrinol Metab. 2016;311(3):E620\u20137. https:\/\/doi.org\/10.1152\/ajpendo.00069.2016.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3302_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"M Turton","year":"1996","unstructured":"Turton M, Shea D, Gunn I, Beak S. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69\u201372. https:\/\/doi.org\/10.1038\/379069a0.","journal-title":"Nature"},{"issue":"Suppl. 1","key":"3302_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jdi.12464","volume":"7","author":"K Katsurada","year":"2016","unstructured":"Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. 2016;7(Suppl. 1):64\u20139. https:\/\/doi.org\/10.1111\/jdi.12464.","journal-title":"J Diabetes Investig"},{"key":"3302_CR7","doi-asserted-by":"publisher","unstructured":"Grieco M, Giorgi A, Gentile MC, d\u2019Erme M, Morano S, Maras B, et al. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases Front Neurosci 2019;13:1112. https:\/\/doi.org\/10.3389\/fnins.2019.01112","DOI":"10.3389\/fnins.2019.01112"},{"issue":"10","key":"3302_CR8","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.2337\/dc19-2316","volume":"43","author":"J Rosenstock","year":"2020","unstructured":"Rosenstock J, Nino A, Soffer J, Erskine L, Acusta A, Dole J, et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care. 2020;43(10):2509\u201318. https:\/\/doi.org\/10.2337\/dc19-2316.","journal-title":"Diabetes Care"},{"key":"3302_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. https:\/\/doi.org\/10.3389\/fendo.2019.00155.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3302_CR10","doi-asserted-by":"publisher","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 2022:1\u201319. https:\/\/doi.org\/10.1007\/s11154-021-09699-1","DOI":"10.1007\/s11154-021-09699-1"},{"issue":"4","key":"3302_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.15406\/aowmc.2020.10.00312","volume":"10","author":"T Omer","year":"2020","unstructured":"Omer T. The causes of obesity: an in-depth review. Adv Obes Weight Manag Control. 2020;10(4):90\u20134. https:\/\/doi.org\/10.15406\/aowmc.2020.10.00312.","journal-title":"Adv Obes Weight Manag Control"},{"issue":"2","key":"3302_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1385\/ENDO:13:2:155","volume":"13","author":"SM Grundy","year":"2000","unstructured":"Grundy SM. Metabolic complications of obesity. Endocrine. 2000;13(2):155\u201365. https:\/\/doi.org\/10.1385\/ENDO:13:2:155.","journal-title":"Endocrine"},{"issue":"1","key":"3302_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/jcp.25855","volume":"233","author":"G Maurizi","year":"2018","unstructured":"Maurizi G, Della Guardia L, Maurizi A, Poloni A. Adipocytes properties and crosstalk with immune system in obesity-related inflammation. J Cell Physiol. 2018;233(1):88\u201397. https:\/\/doi.org\/10.1002\/jcp.25855.","journal-title":"J Cell Physiol"},{"issue":"7121","key":"3302_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860\u20137. https:\/\/doi.org\/10.1038\/nature05485.","journal-title":"Nature"},{"issue":"7394","key":"3302_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature10986","volume":"484","author":"MA Herman","year":"2012","unstructured":"Herman MA, Peroni OD, Villoria J, Sch\u00f6n MR, Abumrad NA, Bl\u00fcher M, Klein S, Kahn BB. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature. 2012;484(7394):333\u20138. https:\/\/doi.org\/10.1038\/nature10986.","journal-title":"Nature"},{"issue":"3","key":"3302_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3945\/jn.108.097618","volume":"139","author":"M Lutter","year":"2009","unstructured":"Lutter M, Nestler EJ. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr. 2009;139(3):629\u201332. https:\/\/doi.org\/10.3945\/jn.108.097618.","journal-title":"J Nutr"},{"issue":"45","key":"3302_CR17","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.1523\/JNEUROSCI.2338-16.2016","volume":"36","author":"CR Ferrario","year":"2016","unstructured":"Ferrario CR, Labou\u00e8be G, Liu S, Nieh EH, Routh VH, Xu S, O\u2019Connor EC. Homeostasis Meets Motivation in the Battle to Control Food Intake. J Neurosci. 2016;36(45):11469\u201381. https:\/\/doi.org\/10.1523\/JNEUROSCI.2338-16.2016.","journal-title":"J Neurosci"},{"key":"3302_CR18","doi-asserted-by":"publisher","unstructured":"Welle S, Campbell RG. Stimulation of thermogenesis by carbohydrate overfeeding. Evidence against sympathetic nervous system mediation. J Clin Invest 1983;71(4):916\u201325. https:\/\/doi.org\/10.1172\/jci110846.","DOI":"10.1172\/jci110846"},{"issue":"6","key":"3302_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/j.1550-8528.1997.tb00590.x","volume":"5","author":"JB Young","year":"1997","unstructured":"Young JB, Landsberg L. Suppression of sympathetic nervous system during fasting. Obes Res. 1997;5(6):646\u20139. https:\/\/doi.org\/10.1002\/j.1550-8528.1997.tb00590.x.","journal-title":"Obes Res"},{"issue":"8","key":"3302_CR20","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.euroneuro.2014.05.005","volume":"24","author":"S Hesse","year":"2014","unstructured":"Hesse S, van de Giessen E, Zientek F, Petroff D, Winter K, Dickson JC, et al. Association of central serotonin transporter availability and body mass index in healthy Europeans. Eur Neuropsychopharmacol. 2014;24(8):1240\u20137. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.05.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3302_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3389\/fpsyg.2014.00919","volume":"5","author":"K Blum","year":"2014","unstructured":"Blum K, Thanos PK, Gold MS. Dopamine and glucose, obesity, and reward deficiency syndrome. Front Psychol. 2014;5:919. https:\/\/doi.org\/10.3389\/fpsyg.2014.00919.","journal-title":"Front Psychol"},{"issue":"6","key":"3302_CR22","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1210\/jcem.87.6.8738","volume":"87","author":"PJ English","year":"2002","unstructured":"English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002;87(6):2984. https:\/\/doi.org\/10.1210\/jcem.87.6.8738.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3302_CR23","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1172\/JCI9842","volume":"105","author":"K El-Haschimi","year":"2000","unstructured":"El-Haschimi K, Pierroz DD, Hileman SM, Bj\u00f8rbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105(12):1827\u201332. https:\/\/doi.org\/10.1172\/JCI9842.","journal-title":"J Clin Invest"},{"issue":"3","key":"3302_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","volume":"23","author":"B Kim","year":"2012","unstructured":"Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab. 2012;23(3):133\u201341. https:\/\/doi.org\/10.1016\/j.tem.2011.12.004.","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"3302_CR25","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/oby.2009.264","volume":"17","author":"DM Arble","year":"2009","unstructured":"Arble DM, Bass J, Laposky AD, Vitaterna MH, Turek FW. Circadian timing of food intake contributes to weight gain. Obesity (Silver Spring). 2009;17(11):2100\u20132. https:\/\/doi.org\/10.1038\/oby.2009.264.","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"3302_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/oem.58.11.747","volume":"58","author":"B Karlsson","year":"2001","unstructured":"Karlsson B, Knutsson A, Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med. 2001;58(11):747\u201352. https:\/\/doi.org\/10.1136\/oem.58.11.747.","journal-title":"Occup Environ Med"},{"key":"3302_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.metabol.2018.12.012","volume":"92","author":"SM Oussaada","year":"2019","unstructured":"Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, et al. The pathogenesis of obesity. Metabolism. 2019;92:26\u201336. https:\/\/doi.org\/10.1016\/j.metabol.2018.12.012.","journal-title":"Metabolism"},{"issue":"2","key":"3302_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.23736\/S2724-6507.20.03369-6","volume":"46","author":"DE Perez-Montes","year":"2021","unstructured":"Perez-Montes DE, Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol (Torino). 2021;46(2):168\u201376. https:\/\/doi.org\/10.23736\/S2724-6507.20.03369-6.","journal-title":"Minerva Endocrinol (Torino)"},{"key":"3302_CR29","doi-asserted-by":"publisher","unstructured":"Barrea L, Pugliese G, Muscogiuri G, Laudisio D, Colao A, Savastano S. New-generation anti-obesity drugs: naltrexone\/bupropion and liraglutide An update for endocrinologists and nutritionists. Minerva Endocrinol 2020;45(2):127\u2013137. https:\/\/doi.org\/10.23736\/S0391-1977.20.03179-X.","DOI":"10.23736\/S0391-1977.20.03179-X"},{"issue":"3","key":"3302_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7570\/jomes21033","volume":"30","author":"DH Ryan","year":"2021","unstructured":"Ryan DH. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? J Obes Metab Syndr. 2021;30(3):196\u2013208. https:\/\/doi.org\/10.7570\/jomes21033.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"3302_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/obr.12839","volume":"20","author":"GA Christou","year":"2019","unstructured":"Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obesity Rev. 2019;20(6):805\u201315. https:\/\/doi.org\/10.1111\/obr.12839.","journal-title":"Obesity Rev"},{"issue":"9","key":"3302_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242\u201351. https:\/\/doi.org\/10.1111\/dom.12932.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3302_CR33","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","volume":"221","author":"L van Bloemendaal","year":"2014","unstructured":"van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1-16. https:\/\/doi.org\/10.1530\/JOE-13-0414.","journal-title":"J Endocrinol"},{"issue":"3","key":"3302_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1172\/JCI81335","volume":"127","author":"RP Gaykema","year":"2017","unstructured":"Gaykema RP, Newmyer BA, Ottolini M, Raje V, Warthen DM, Lambeth PS, et al. Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. J Clin Invest. 2017;127(3):1031\u201345. https:\/\/doi.org\/10.1172\/JCI81335.","journal-title":"J Clin Invest"},{"issue":"10","key":"3302_CR35","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF, Hecksher-S\u00f8rensen J, Cowley MA, Dalb\u00f8ge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473\u201388. https:\/\/doi.org\/10.1172\/JCI75276.","journal-title":"J Clin Invest"},{"issue":"1","key":"3302_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/db15-0973","volume":"65","author":"JP Krieger","year":"2016","unstructured":"Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes. 2016;65(1):34\u201343. https:\/\/doi.org\/10.2337\/db15-0973.","journal-title":"Diabetes"},{"issue":"3","key":"3302_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754\u201362. https:\/\/doi.org\/10.1111\/dom.14280.","journal-title":"Diabetes Obes Metab"},{"issue":"10286","key":"3302_CR38","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(21)00845-X.","journal-title":"Lancet"},{"issue":"10148","key":"3302_CR39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O'Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(18)31773-2.","journal-title":"Lancet"},{"key":"3302_CR40","doi-asserted-by":"publisher","unstructured":"Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring) 2020;28(6):1050\u201361. https:\/\/doi.org\/10.1002\/oby.22794","DOI":"10.1002\/oby.22794"},{"key":"3302_CR41","doi-asserted-by":"publisher","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","DOI":"10.1056\/NEJMoa2032183"},{"key":"3302_CR42","doi-asserted-by":"publisher","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. STEP 2 Study Group. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"3302_CR43","doi-asserted-by":"publisher","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021;325(14):1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","DOI":"10.1001\/jama.2021.1831"},{"key":"3302_CR44","doi-asserted-by":"publisher","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021;325(14):1414\u201325. https:\/\/doi.org\/10.1001\/jama.2021.3224.","DOI":"10.1001\/jama.2021.3224"},{"key":"3302_CR45","unstructured":"Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 5). [cited 2021 Feb 05]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03693430"},{"issue":"3","key":"3302_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206. https:\/\/doi.org\/10.1016\/S2213-8587(22)00008-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3302_CR47","unstructured":"Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 7). [cited 2021 Feb 07]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04251156."},{"key":"3302_CR48","unstructured":"Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity (STEP 8). [cited 2021 Feb 07]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04074161."},{"issue":"2","key":"3302_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"3302_CR50","unstructured":"STEP TEENS: A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity. [cited 2021 Feb 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04102189."},{"key":"3302_CR51","unstructured":"Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT). [cited 2021 Feb 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03574597."},{"key":"3302_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2020.07.008.","journal-title":"Am Heart J"},{"key":"3302_CR53","unstructured":"Novo Nordisk: Company announcements. Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management. [cited 2021 Jan 15]. Available from: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=37551"},{"key":"3302_CR54","unstructured":"Novo Nordisk: Company announcements. Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management. [cited 2021 Jan 28]. Available from: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/736c741c-98e9-4518-a98b-15975f68d5e1"},{"key":"3302_CR55","unstructured":"Novo Nordisk Company Announcements. Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide. [cited 2021 Apr 21]. Available from: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/3e7d1e68-06dd-4417-afc8-8f5ac1ee8367"},{"key":"3302_CR56","unstructured":"Novo Nordisk: Company announcements. Wegovy\u2122 (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US. [cited 2021 Jul 08]. Available from: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/77d24f13-7de0-4032-8239-efed71e6e0bf"},{"key":"3302_CR57","unstructured":"Novo Nordisk: Company announcements. WegovyTM recommended for approval for the treatment of obesity by the European regulatory authorities. [cited 2022 January 21]. Available from: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=86334"},{"issue":"1","key":"3302_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/hepr.12333","volume":"45","author":"E Hashimoto","year":"2015","unstructured":"Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45(1):20\u20138. https:\/\/doi.org\/10.1111\/hepr.12333.","journal-title":"Hepatol Res"},{"issue":"1","key":"3302_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pin.12485","volume":"67","author":"M Sakamoto","year":"2017","unstructured":"Sakamoto M, Tsujikawa H, Effendi K, Ojima H, Harada K, Zen Y, et al. Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Pathol Int. 2017;67(1):1\u20137. https:\/\/doi.org\/10.1111\/pin.12485.","journal-title":"Pathol Int"},{"key":"3302_CR60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","volume":"179","author":"N Tanaka","year":"2017","unstructured":"Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142\u201357. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.011.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"3302_CR61","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901\u201310. https:\/\/doi.org\/10.1016\/S2213-8587(14)70032-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3302_CR62","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fendo.2018.00649","volume":"9","author":"M Seghieri","year":"2018","unstructured":"Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsb\u00f8ll T. Future Perspectives on GLP-1 Receptor Agonists and GLP-1\/glucagon Receptor Co-agonists in the Treatment of NAFLD. Front Endocrinol (Lausanne). 2018;9:649. https:\/\/doi.org\/10.3389\/fendo.2018.00649.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3302_CR63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3748\/wjg.v25.i2.163","volume":"25","author":"N Tanaka","year":"2019","unstructured":"Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol. 2019;25(2):163\u201377. https:\/\/doi.org\/10.3748\/wjg.v25.i2.163.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3302_CR64","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","volume":"45","author":"F Bril","year":"2016","unstructured":"Bril F, Cusi K. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am. 2016;45(4):765\u201381. https:\/\/doi.org\/10.1016\/j.ecl.2016.06.005.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"3302_CR65","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584\u201392. https:\/\/doi.org\/10.1002\/hep.23569.","journal-title":"Hepatology"},{"issue":"1","key":"3302_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/en.2012-1937","volume":"154","author":"N Panjwani","year":"2013","unstructured":"Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice. Endocrinology. 2013;154(1):127\u201339. https:\/\/doi.org\/10.1210\/en.2012-1937.","journal-title":"Endocrinology"},{"issue":"11","key":"3302_CR67","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4254\/wjh.v10.i11.790","volume":"10","author":"M Kalogirou","year":"2018","unstructured":"Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol. 2018;10(11):790\u20134. https:\/\/doi.org\/10.4254\/wjh.v10.i11.790.","journal-title":"World J Hepatol"},{"issue":"4","key":"3302_CR68","doi-asserted-by":"publisher","first-page":"518","DOI":"10.21037\/hbsn-2021-13","volume":"10","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. Hepatobiliary Surg Nutr. 2021;10(4):518\u201321. https:\/\/doi.org\/10.21037\/hbsn-2021-13.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"3302_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087488","volume":"9","author":"C Bernsmeier","year":"2014","unstructured":"Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS ONE. 2014;9(1): e87488. https:\/\/doi.org\/10.1371\/journal.pone.0087488.","journal-title":"PLoS ONE"},{"issue":"1","key":"3302_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/clinem\/dgab578","volume":"107","author":"C Patel Chavez","year":"2022","unstructured":"Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022;107(1):29\u201338. https:\/\/doi.org\/10.1210\/clinem\/dgab578.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3302_CR71","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020;43(6):1352\u20135. https:\/\/doi.org\/10.2337\/dc19-1892.","journal-title":"Diabetes Care"},{"issue":"5","key":"3302_CR72","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-8587(17)30109-2","volume":"5","author":"N Katsiki","year":"2017","unstructured":"Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol. 2017;5(5):329\u201330. https:\/\/doi.org\/10.1016\/S2213-8587(17)30109-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3302_CR73","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G, Rolin B, N\u00f8hr J, Klewe I, Frederiksen KS, Augustin R, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-\/- and LDLr-\/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844\u201357. https:\/\/doi.org\/10.1016\/j.jacbts.2018.09.004.","journal-title":"JACC Basic Transl Sci"},{"key":"3302_CR74","doi-asserted-by":"publisher","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. NN9931\u20134296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395","DOI":"10.1056\/NEJMoa2028395"},{"key":"3302_CR75","unstructured":"Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH). [cited 2021 May 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03987074"},{"key":"3302_CR76","unstructured":"Novo Nordisk Press Release: Gilead and Novo Nordisk present new data from proof-of concept trial in NASH. [cited 2021 May 25]. Available from: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1fb7fd74-0c03-46ef-9c84-4ae5e5855766"},{"key":"3302_CR77","unstructured":"A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage. [cited 2021 Feb 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03987451"},{"key":"3302_CR78","unstructured":"Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH). [cited 2022 January 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04822181"},{"key":"3302_CR79","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.trsl.2016.12.005","volume":"183","author":"T Diehl","year":"2017","unstructured":"Diehl T, Mullins R, Kapogiannis D. Insulin resistance in Alzheimer\u2019s disease. Transl Res. 2017;183:26\u201340. https:\/\/doi.org\/10.1016\/j.trsl.2016.12.005.","journal-title":"Transl Res"},{"key":"3302_CR80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145\u2013146","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T. Insulin resistance and Parkinson\u2019s disease: A new target for disease modification? Prog Neurobiol. 2016;145\u2013146:98\u2013120. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.10.001.","journal-title":"Prog Neurobiol"},{"issue":"Pt B","key":"3302_CR81","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","volume":"136","author":"C H\u00f6lscher","year":"2018","unstructured":"H\u00f6lscher C. Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology. 2018;136(Pt B):251\u20139. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.040.","journal-title":"Neuropharmacology"},{"key":"3302_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol. 2020;180: 114187. https:\/\/doi.org\/10.1016\/j.bcp.2020.114187.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3302_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","volume":"29","author":"C H\u00f6lscher","year":"2020","unstructured":"H\u00f6lscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs. 2020;29(4):333\u201348. https:\/\/doi.org\/10.1080\/13543784.2020.1738383.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"3302_CR84","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JPD-200002","volume":"10","author":"K McFarthing","year":"2020","unstructured":"McFarthing K, Larson D, Simuni T. Clinical Trial Highlights - GLP-1 agonists. J Parkinsons Dis. 2020;10(2):355\u201368. https:\/\/doi.org\/10.3233\/JPD-200002.","journal-title":"J Parkinsons Dis"},{"issue":"24","key":"3302_CR85","doi-asserted-by":"publisher","first-page":"505","DOI":"10.21037\/atm.2017.11.10","volume":"5","author":"JJ Holst","year":"2017","unstructured":"Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017;5(24):505. https:\/\/doi.org\/10.21037\/atm.2017.11.10.","journal-title":"Ann Transl Med"},{"issue":"6","key":"3302_CR86","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6): e133429. https:\/\/doi.org\/10.1172\/jci.insight.133429.","journal-title":"JCI Insight"},{"issue":"1","key":"3302_CR87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"key":"3302_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang L, Li L, H\u00f6lscher C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides. 2018;71:70\u201380. https:\/\/doi.org\/10.1016\/j.npep.2018.07.003.","journal-title":"Neuropeptides"},{"issue":"1","key":"3302_CR89","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang L, Li L, H\u00f6lscher C. Semaglutide is Neuroprotective and Reduces \u03b1-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson\u2019s Disease. J Parkinsons Dis. 2019;9(1):157\u201371. https:\/\/doi.org\/10.3233\/JPD-181503.","journal-title":"J Parkinsons Dis"},{"key":"3302_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107748","volume":"158","author":"X Yang","year":"2019","unstructured":"Yang X, Feng P, Zhang X, Li D, Wang R, Ji C, et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology. 2019;158: 107748. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107748.","journal-title":"Neuropharmacology"},{"key":"3302_CR91","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","volume":"81","author":"YF Chang","year":"2020","unstructured":"Chang YF, Zhang D, Hu WM, Liu DX, Li L. Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apoptosis. J Clin Neurosci. 2020;81:234\u20139. https:\/\/doi.org\/10.1016\/j.jocn.2020.09.054.","journal-title":"J Clin Neurosci"},{"key":"3302_CR92","unstructured":"Novo Nordisk Company Announcement: Novo Nordisk to enter phase 3 development in Alzheimer\u2019s disease with oral semaglutide. [cited 2021 Feb 15]. Available from: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/e379383d-436d-462d-907b-87fb87afe234"},{"key":"3302_CR93","unstructured":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE). [cited 2022 January 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04777396"},{"key":"3302_CR94","unstructured":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus). [cited 20221 January 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04777409"},{"key":"3302_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.666737","volume":"12","author":"AN MacMahon Copas","year":"2021","unstructured":"MacMahon Copas AN, McComish SF, Fletcher JM, Caldwell MA. The Pathogenesis of Parkinson\u2019s Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes? Front Neurol. 2021;12: 666737. https:\/\/doi.org\/10.3389\/fneur.2021.666737.","journal-title":"Front Neurol"},{"key":"3302_CR96","unstructured":"GLP1R in Parkinson's Disease (GIPD). [cited 2021 Feb 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03659682."},{"issue":"9","key":"3302_CR97","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/13543784.2017.1360274","volume":"26","author":"X Tan","year":"2017","unstructured":"Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2017;26(9):1083\u20139. https:\/\/doi.org\/10.1080\/13543784.2017.1360274.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"3302_CR98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3302_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(17)30092-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3302_CR100","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, Pileti\u010d M, Rose L, Axelsen M, Rowe E, DeVries JH. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(17)30085-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3302_CR101","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378\u201388. https:\/\/doi.org\/10.1111\/dom.13082.","journal-title":"Diabetes Obes Metab"},{"key":"3302_CR102","doi-asserted-by":"publisher","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","DOI":"10.1056\/NEJMoa1607141"},{"key":"3302_CR103","unstructured":"Ozempic Product Monograph. Available at: https:\/\/www.novonordisk.ca\/content\/dam\/nncorp\/ca\/en\/products\/ozempic-product-monograph.pdf Assessed on Oct 5, 2021."},{"key":"3302_CR104","unstructured":"Rybelsus Product Monograph. Available at: https:\/\/www.novonordisk.ca\/content\/dam\/nncorp\/ca\/en\/products\/Rybelsus-PM-EN-monograph.pdf Assessed on October 5, 2021."},{"key":"3302_CR105","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.20.03219-8","author":"B Nreu","year":"2020","unstructured":"Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2020. https:\/\/doi.org\/10.23736\/S0391-1977.20.03219-8.","journal-title":"Minerva Endocrinol"},{"key":"3302_CR106","unstructured":"European Medicines Agency. Ozempic; summary of product characteristics. 2020. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004174\/WC500244163.pdf. Assessed on June 18, 2021."},{"key":"3302_CR107","unstructured":"European Medicines Agency. Rybelsus; summary of product characteristics. 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf. Assessed on June 18, 2021."},{"issue":"3","key":"3302_CR108","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, Lingvay I, S\u00f8rrig R, Treppendahl MB, Vilsb\u00f8ll T. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442\u201351. https:\/\/doi.org\/10.1111\/dom.13955.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3302_CR109","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2015;55(5):497\u2013504. https:\/\/doi.org\/10.1002\/jcph.443.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"3302_CR110","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40262-017-0532-6","volume":"56","author":"H Hausner","year":"2017","unstructured":"Hausner H, Derving Karsb\u00f8l J, Holst AG, Jacobsen JB, Wagner FD, Golor G, Anderson TW. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017;56(11):1391\u2013401. https:\/\/doi.org\/10.1007\/s40262-017-0532-6.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3302_CR111","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","volume":"58","author":"TA B\u00e6kdal","year":"2019","unstructured":"B\u00e6kdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Clin Pharmacokinet. 2019;58(9):1193\u2013203. https:\/\/doi.org\/10.1007\/s40262-019-00756-2.","journal-title":"Clin Pharmacokinet"},{"key":"3302_CR112","doi-asserted-by":"publisher","unstructured":"Jordy AB, Albayaty M, Breitschaft A, Anderson TW, Christiansen E, Houshmand-\u00d8regaard A, Manigandan E, B\u00e6kdal TA. Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. Clin Pharmacokinet. 2021. https:\/\/doi.org\/10.1007\/s40262-020-00976-x","DOI":"10.1007\/s40262-020-00976-x"},{"issue":"8","key":"3302_CR113","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/17425255.2018.1488965","volume":"14","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Breitschaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14(8):869\u201377. https:\/\/doi.org\/10.1080\/17425255.2018.1488965.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3302_CR114","unstructured":"A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times. [Cited 2022 January 21]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04615871"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03302-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03302-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03302-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:36:51Z","timestamp":1744187811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03302-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3302"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03302-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}